Trump Sparks A 2025 IPO Boom: 5 New Stocks Have Rallied Over 400%

The IPO market is coming back to life in 2025, fueled by a favorable business climate under President Donald Trump’s second term and a burst in investor demand for new equity stories as risk sentiment runs at full throttle on Wall Street.So far in 2025, 163 companies have gone public in the U.S., marking a 49.5% increase over the 109 IPOs of 2024. Total proceeds collected this year have reached $31 billion, a 17.1% rise from last year, and there's still a full quarter left to go.The revival stands in stark contrast to the post-2021 cooldown, when high borrowing costs and rampant inflation had all but frozen new listings. While still far from the frothy heights of 2021 — when 397 IPOs raised a staggering $142.4 billion — the IPO market is showing its strongest momentum in four years.Biggest Quarter For IPO Market Since 2021According to Renaissance Capital, the third quarter of 2025 marked a turning point. The U.S. IPO market saw 64 deals that raised $15.3 billion, making it the most active quarter since 2021."Renewed interest in growth stocks allowed many of these names to price above the midpoint," Renaissance said, noting a steady ramp-up in issuance from July through September. Twenty-four IPOs raised over $100 million, led by headline names like Etoiles Capital Group Co. Ltd. (NASDAQ:EFTY) with $5.6 billion, Klarna Group plc (NYSE:KLAR) with $1.3 billion and Figma Inc. (NYSE:FIG) with $1.2 billion. Figma, in particular, electrified Wall Street with a stunning 250% surge on its trading debut.The shift in sentiment is also being reflected in market performance. The Renaissance IPO ETF (NYSE:IPO), which tracks the performance of newly listed companies, is now outperforming the SPDR S&P 500 ETF Trust (NYSE:SPY) by roughly 1% in 2025, after lagging the benchmark by more than 6 percentage points last year.Five IPOs Have Already Gained Over 400%—Did You Miss the Rally?IPO returns have been staggering for a select few. Below are five standout performers that have surged more than 400% since debuting this year.5) Anbio Biotechnology (NASDAQ:NNNN)Specializing in diagnostic and point-of-care biotech solutions, Anbio's February IPO priced at $5.00. Shares have soared to $28.27, a 470.34% gain despite recent volatility.4) Diginex Ltd. (NASDAQ:DGNX)A fast-growing software company specializing in decentralized digital identity and compliance tools, Diginex raised $9 million in January. The stock has risen 492.88% since its $4.00 IPO.3) Rich Sparkle Holdings Ltd. (NASDAQ:ANPA)A provider of commercial support services in Southeast Asia, Rich Sparkle listed in July at $4.00 per share. Its current price of $27.40 marks a 585% surge.2) Jyong Biotech Ltd. (NASDAQ:MENS)This biotech firm, which focuses on hormone-related therapies, has exploded since its June debut. From an IPO price of $7.00, the stock now trades at $52.23, up 647.27%, giving it a market cap of over $4 billion.1) Epsium Enterprise Ltd. (NASDAQ:EPSM)A distributor operating in niche industrial sectors, Epsium debuted in March at $4.00. Shares now trade at $32.30, up 707.63%. The company raised just $5 million through a modest 1.25 million share offering. Going All-In On US AI Stocks? You’re Missing The China Trade, Alpine Macro Says Image created using photos from Shutterstock.